KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3.

Roy Yaari, Karen C Holdridge, Melissa Williamson, Alette M Wessels, Sergey Shcherbinin, Vikas Kotari, Eric M Reiman, Pierre N Tariot, Robert Alexander, Jessica B Langbaum, John R Sims

Alzheimers Dement 21(9) e70662

PMID40955720
PMCIDPMC12439032
DOI10.1002/alz.70662
发表日期2025-09-16
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other;FIGURE 3:森林图/亚组分析图;FIGURE 4:森林图/亚组分析图。
摘要

摘要

INTRODUCTION: TRAILBLAZER-ALZ 3 is investigating donanemab in preclinical Alzheimer's disease (AD). METHODS: This double-blind, placebo-controlled trial used a plasma phosphorylated tau-217 (p-tau217) assay to detect AD pathology for eligibility and a decentralized design to enhance screening and enrollment. After nine monthly infusions, clinical assessments continue every 6 months with a time-to-event primary outcome. A sub-study will evaluate longitudinal changes in amyloid and tau positron emission tomography (PET). RESULTS: Participants 55-80 years of age were screened (N = 63,124). Plasma p-tau217-eligible participants were enrolled (N = 2196), with Clinical Dementia Rating (CDR) scale-Global score (CDR-GS) of 0 (n = 1202) and 0.5 (n = 664). Plasma p-tau217 eligibility increased with age, differing across races and ethnicities. Mean baseline amyloid levels were 63.2 (CDR-GS: 0) and 70.7 Centiloids (CDR-GS: 0.5). Elevated global tau signal (standardized uptake value ratio ≥1.10) was observed in 15.1% and 26.3% of CDR-GS 0 and 0.5 subgroups, respectively. DISCUSSION: Utilizing a unique decentralized design, the trial showed baseline data consistent with preclinical AD. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05026866, TRAILBLAZER-ALZ 3 HIGHLIGHTS: TRAILBLAZER-ALZ 3 screened 63,124 participants in the United States and Japan Plasma phosphorylated tau-217 (p-tau217) was used to determine Alzheimer's disease pathology for eligibility A decentralized model was used, including remote raters for clinical testing Randomized participants had Clinical Dementia Rating scale-Global scores of 0 and 0.5.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Diagram of participants screened, reasons for screen failure, and number of participants randomized. CDR‐GS, Clinical Dementia Rating scale–Global score; MRI, magnetic resonance imaging; p‐tau, phosphorylated tau; TICS‐m, Telephone Interview for Cognitive Status–modified.
非 KM Figure
FIGURE 2Race and ethnicity distribution of participants screened and randomized in the TRAILBLAZER‐ALZ 3 study.
非 KM Figure
FIGURE 3Average baseline tau deposition for participants in the LEARN, A4, and TRAILBLAZER‐ALZ 3 studies by CDR‐GS subgroup and for TRAILBLAZER‐ALZ 2 participants with a baseline CDR‐GS of 0.5. *Tau‐positive and high tau cutoff derived from Mintun et al, 2021. 24 A4, Anti‐Amyloid Treatment in Asymptomatic Alzheimer's; AD, Alzheimer's disease; CDR‐GS, Clinical Dementia Rating scale–Global score; LEARN, Longitudinal Evaluation of Amyloid Risk and Neurodegeneration; n, number of participants; SUVR, standardized uptake value ratio; VOI, volume of interest.
非 KM Figure
FIGURE 4Regional baseline tau deposition for participants in the LEARN, A4, and TRAILBLAZER‐ALZ 3 studies by CDR‐GS subgroup and for TRAILBLAZER‐ALZ 2 participants with a baseline CDR‐GS of 0.5. A4, Anti‐Amyloid Treatment in Asymptomatic Alzheimer's; CDR‐GS, Clinical Dementia Rating scale–Global score; LEARN, Longitudinal Evaluation of Amyloid Risk and Neurodegeneration; SUVR, standardized uptake value ratio.
非 KM Figure